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Protein kinase C (PKC) activity and DNA synthesis were measured in human fetal bone marrow fibroblasts following treatment with tumor necrosis 
factor alpha (TNF~) (500 U/ml) or conditioned media containing natural ceil proliferation inhibitor (CM-NCPI). Treatment with TNFa led to 
growth stimulation (120 + 7% of control in 24 h, 141 +_ 6% in 72 h). At the same time particulate PKC activity diminished, reaching 55 + 8% of 
control in 24 h and remaining at this level at 72 h, CM-NCPI treatment of the cells resulted in a decrease in DNA synthesis (by 39 -- 6% in 2 h, 
by 58 +_ 5% in 24 h, and by 78 ~" 8% in 72 h), This was accompanied by a significant rise in particulate PKC activity which increased over 3-fold 
in 2 h, over 5-fold in 24 h, and up to 11.fold in 72 h. This I l-fold elevation was maintained after 2 week exposure of the fibroblasts to CM-NCPI, 
The PKC inhibitor neon'tycin abolished CM-NCPI induced growth inhibition, whereas PKC activator 12.O.tetradec.anoylphorbol 13.ac.etate 
intensified it, These results uggest hat CM-NCPI acts as PKC activator and that negative growth regulation by extracellular gents may involve 
stimulation of PKC activity. 
Protein kinase C; Growth inhibitor; Tumor necrosis factor; Fibroblast 
1, INTRODUCTION 
Study of protein kinase C (PKC)-phospholipid-de- 
pendent serine-threonine protein kinase appears to be 
of particular importance for the understanding of cell 
growth regulation [1-4]. It is accepted that this family 
of enzymes plays a 'pivotal role' in intracellular signal 
transduction [2]. PKC-dependent signalling is a com- 
plex multifactorial process which is only partly under- 
stood. Initially, most of the researchers associated the 
increase in PKC activity with the stimulation of cell 
growth [5]. Recently, however, it was proven that PKC 
can inhibit cell growth and tumor promotion [6]. For 
that reason the study of the effects of negative regula- 
tors on PKC seems likely to provide a deeper insight 
into mechanisms of cell growth inhibition. 
In the present work we have studied the cytokine 
influence on PKC activity and its correlation with DNA 
synthesis in human fetal fibroblasts. Two agents were 
used: tumor necrosis factor alpha (TNFct), which is a 
negative regulator for many cell types 17], and fibro- 
blast-derived conditioned medium containing a nega- 
tive regulator named NCPI (CM-NCPI) that has been 
described by us previously [8]. In the research per- 
formed we observed that induced inhibition of fibro- 
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blast growth is associated with a long-term increase in 
particulate PKC activity. 
2. MATERIALS AND METHODS 
2. l. Preparation of condit/oned med/um containing NCPI 
Human fetal bone marrow fibroblasts (1 x lff') were g~:led in 175 
cm z flasks in RPMI.1640 medium with 20% fetal bovine serum (FBS), 
Afterwards, cells were incubated for 2-4 weeks. The ability ofcondi. 
tioned media to suppress fihroblast proliferation was periodically 
tested by DNA synthesis assay, Conditioned media were c.olleeted, 
filtered through 0.45 ~um filters, and either used immediately or frozen 
at -70°C for later use. 
2.2. TNF~ 
TNFa was obtained from Hayashibara Laboratories 
(Okaymna, Japan), lot no. 005001. 
|he. 
2.2.2. Fibroblast cultures 
Human fetal bone marrow fibroblasts ~,ere maintained in RPMl- 
1640 medium supplemented with 20% heat-inactivated fetal bovine 
serum in a humidified atmosphere of :5% carbon dioxide:95% air. 
Confluent cells were harvested and re-seeded in 12.well plates or 175 
cm ~ flasks as needed. The medimn was changed every 3 days and 24 
h prior to all studies. The human bone marrow fibroblast cell line, BM 
5.1, was used in all experiments, 
To study the elT~ts of  negative regulators 106 ~lls were seeded in 
175 cm-" flasks in RPMI-1640 medium with 20% FBS and grown to 
20-30% confluence. The medium was then replaced with fresh medium 
(control) or one containing TNFcz (500 U/ml) or CM-NCPI diluted 
1:2. 
2.3. /'reparation ~ ceittdar fi'aclion.~" 
Ceils grown in 175 cm a flasks were washed twice with Ca"- ,  M~*- 
free Dulbeceo's phosphate buffered saline (PBS) and resuspended in
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buffer A containing 20 mM Tris-HCI. pH 7,5, 2 mM EDTA, 2 mM 
EGTA, 1 mM phenylmPthylsulfonyI lluoride (PMSF) and 50 pg/ml 
leupcptin. Cells were disrupted with SO strokes in a tight-fittingglass- 
glass homogenizer. The homogenate Wits cemrifuged at 50,000 x g for 
60 min and thccytosol was removed. The membrane pcllst was washed 
with buffer A and resuspended in the same buffer. Aliquots were taken 
for protein determination by the Lowry mclhod [!I]. Triton X.100 was 
added to the resuspended particulate fraction to 0.2% final concenlra. 
tion. After 45 min incubnlion at 4°C the membrane suspension was 
centrifuged at 50.000 x 6 for 60 min. The supernalant containing the 
solubilized membrane fraction was colleclcd. 
2.4. PKC ocriviry assq 
The PKC enzyme assay system (Amersham. UK) was used lo deter- 
mice PKC aciivity of cellular fractions. The determination was based 
on the transfer of IzP from [y-“P]ATP to a synthetic pcptide. The assay 
mixture (50~1) was prepured by the addition of35 ~1 ofdiluted cellular 
extracts, containing 5 AU& of protein, to 25 ,ul of freshly prepared 
reagent mixture (3 mM calcium actate, 2 mole % L-phosphatidyl 
serine, 6 ,@nll phorbol I?-myristate acetate, 7.5 mM dithiothreitol 
(DTT) and 225 PM of peptide in 50 mM Tris-HCI, pH 7.5). The 
reaction was initiated by the addition of I PCi of [y-“P]ATP in 25 yl 
of 150pM ATP, 45 mM magnesium acetale, 50 mM Trin-HCI, pH 7.5, 
into the assay mixture. After 20 min incubation the reaction was 
terminated by adding 100 ~1 of stop reagent (PKC enzyme assay 
system, Amersham), and 12.5 ~1 aliquots were transferred to 2.5 x 2.5 
cm squares of binding paper. Papers were washed twice with 5% acetic 
acid and courtled in 5 ml of Scintiversc (Fisher, Pitlsburg, PA), Kinase 
activity was determined by subtracting ‘:P incorporation into peptide 
in the absence of activators from incorporation in the presence of 
activators. To ensure complete absence of free calcium 3 mM EGTA 
was substiluted for calcium acetate in controls. 
Exponenhally growing human fetal bone marrow fibroblasts were 
trypsinized, washed and seeded onto 12mwell p ates (25,000 cc)ls/well) 
in I.5 ml of RPMI-1640 medium with 20% FBS. After 24 h the 
medium was replaced with fresh medium and the cells were cultured 
for an additional 24 h. The medium was then replaced again with fresh 
medium (control) or wiih one containing the agent of interest in the 
desired conc:nlrations. After 2, 12. 24 or 72 h of treatment 50,~) of 
[3H]thymidine was added and cells were cultured for an additional 3 
h. After 3 h incubation with [2H]thymidinc the cells were washed with 
ice-cold 5% trichloroacetic acid (TCA). TCA-insoluble material was 
solubilized in 0.6 ml NaOH, transferred into scinWation vials with 
ASC scintillation fluid (Packard, CT) and counted using a Tri-Carb 
Liquid Scintillalion Anulyser 190OCA (Packard, CT). 
PMSF, DTT, Triton X-100, leupcplin and neomycin were obtained 
from Sigma Chemical Co. (St. L&s, MO). 12.O-Tetradccanoylphor. 
bol 13-acclate (TPA) was purchased from LC Services Corp, 
(Woburn, MA). TNFo was obtained from Hayashibara Laboratories 
Inc., no. 005001 (Okayuma, Japan). 
3. RESULTS 
PKC activity in human Fetal bone marrow fibroblasts 
BM 5.1, following treatment with TNFa! or CM-NCPI, 
was studied.at different intervals, The cell proliferation 
rate was measured by a I’H]thymidine incorporation 
assay. PKC activity was measured separately in cytosol 
and membrane-derived fractions, 
TNFa treatment of fibroblasts resulted in a slow and 
gradual decline in both cytosolic and particulate PKC 
activity. Particulate PKC activity was 83 r 7% of con- 
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Fig. I. PKC activity and DNA synthesis in human fetal bone marrow 
fibroblasts following treatment with 500 U/ml TNFo. Each set ofdata 
points represents he means of at least three separate xperiments. 
trol in 30 min, 72 _ 5% in 2 h, 55 k 8% in 24 h and 
63 -t 8% in 72 h (Fig. 1). Cytosolic PKC activity 
dropped to 81 + 9% of control in 30 min, 61 + 5% in 2 
h, 56 -t- 8% in 24 h and 62 + 4% in 72 h (Fig. 1). DNA 
synthesis in TNFa-treated cells was suppressed by 
31 f 5% in 2 h, however, the suppression was followed 
by a rise in DNA synthesis to 120 f 7% of control after 
24 h and 141 f 6% after 72 h (Fig. 1). CM-NCPI caused 
substantial elevation in both particulate and cytosolic 
PKC activity. Particulate PKC reached 122 + 9% in 30 
min, 322 136% in 2 h, 559 2 23% in 24 h and 
1090 i 154% in 72 h (Fig. 2). Cytosolic PKC activity 
was94-1- ll%in30min,121 iS%in2h,201 -1_27%in 
24 h and 218 ?. 12% in 72 h (Fig. 2). These elevated 
levels of PKC activity were still present after 2 weeks 
exposure of fibroblasts to the CM-NCPI (dcta not 
shown on the graph). DNA synthesis in CM-NCPI- 
treated fibroblasts was suppressed by 39 & 6% in 2 h, 
58 f 5% in 24 h, and 78 f 8% in 72 h (Fig. 2). 
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Fig. 2. XC activity and DNA synthesis in human fetal bone marrow 
fibroblasts following treatment with CM-NCPI (dilution 1:2), Each set 
of data points represents he means 01’ at least three $sparatc experi- 
ments. 
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Fig. 3, DNA synthesis in human fetal bone marrow fibroblasts after 
2 h (t) and 12 h (1~) treatment with: NCPI. conditioned medium 
containing NCPI (dilution 1:4); TPA. 12-O-tetradecanoylphorbol 13- 
acetate 10"" M; Neo, neomycin 5 raM; NCPl + TPA, conditioned 
medium containing NCPI and TPA 10 -s M" NCPI ÷ Neo, condi- 
tioned medium containing NCPI and neomycin 5 raM. 
To verify the involvement of PKC in the process of 
cell growth inhibition we studied the influence of the 
PKC inhibitor, neomycin, and the PKC activator, TPA, 
upon the CM-NCPI or TNF~t-induced alteration of fi- 
broblast growth rate. Treatment with 10 -a M TPA st:p- 
pressed DNA synthesis in cells by 32 _ 5% in 2 h, by 
36 _ 4% in 12 h (Fig. 3) and by 48 -!"_ 8% in 24 h. Simul- 
taneous treatment with 10-" M TPA and 500 U/ml 
TNFg caused weaker growth inhibition than TPA 
alone: by 15 +_ 4% in 2 h, 21 +_ 6% in 12 h and 27 ± 5% 
in 24 h. The opposite effect was observed for CM- 
NCPI. Simultaneous treatment with 10 -a M TPA and 
l:4-diluted CM-NCPI synergistically inhibited DNA 
synthesis by 50 _ 6% in2 h, 61 _ 7% in 12 h (Fig. 3) and 
65 _ 6% in 24 h. 
Neomycin at 5 mM had no significant effect on DNA 
synthesis within 12 h, however, it virtually abolished the 
inhibitory effect of CM-NCP1 (90 "2_ 6% of control in 2 
h, 92 ± 4% of control in 12 h, Fig. 3). The effects of 
TNF~ on fibroblast proliferation rate were not altered 
by neomycin. 
4. DISCUSSION 
An unexpected correlation between PKC activity and 
ceU growth inhibition was observed after the treatment 
of fibroblasts with NCPI-containing conditioned media 
(CM-NCPI). We decided to use conditioned medium as 
a crude source of the growth factor, as is common prac- 
tice in similar circumstances [10-12], since the purpose 
of this work was to study the correlation of PKC activ- 
ity with growth regulation. Moreover, the use of PKC 
inhibitor and PKC activator provided an opportunity 
to verify the involvement of PKC in CM-NCPl-induced 
cell growth inhibition. 
We observed significant elevation of both cytosolic 
and particulate PKC activity in association with growth 
inhibition by CM-NCPI. CM-NCPI-induced cell 
growth inhibition was significantly reversal by neomy- 
cin. Neomycin is an inhibitor of phospholipase C (PLC) 
[13,14]; it was shown to bind to phosphatidyl-inositol 
biphosphate (PLP:) and thereby prevents its hydrolysis 
by PLC. As a result, production of  inositol 1,4,5-tri- 
phosphate (IP3) and diacylglycerol (DG) is decreased, 
which leads to PKC activity downfall. On the other 
hand we found that TPA, a well-known PKC activator 
[5,6], significantly inhibited fibroblast growth. These 
observations support he idea that PKC activation may 
in some cases lead to growth inhibition. Simultaneous 
treatment of fibroblasts with CM-NCPI and TPA po- 
tentiated growth inhibition. This may be due to the 
ability of both agents to enhance PKC activity. 
The possibility of  negative regulation via PKC activa- 
tion has been brought up in the literature [3]. The first 
direct evidence of PKC-mediated cell growth inhibition 
was obtained in Weinst¢in's laboratory [6]. A retro- 
virus-derived vector system was used to obtain a PKC- 
overproducing human colon cancer ¢¢11 line which ex- 
hibited growth inhibition in response to TPA. 
Our results indicate that ¢xtracellular signals which 
produce growth inhibitory effects can also cause a sig- 
nificant PKC activation. One could suppose that this 
phenomenon reflects a special PKC-mediated mecha- 
nism of cell growth inhibition. In the ease of  human 
fibroblasts this may be a normal physiological pro~ss. 
Effects of TNFcz on fibroblasts were different from 
those of CM-NCPI in terms of both growth rate altera- 
tion and PKC activity. TNF~ is known to be a negative 
regulator for some cell lines and a stimulator for others 
[7]. The present work shows its mitogenic properties for 
human fetal bone marrow fibroblasts. Our results are 
in accord with the data obtained by Vilceck et al. [15]. 
In addition we found that TNFa-induc,~l stimulation of  
fibroblast growth was preceded by a short-term growth 
suppression lasting for about 12 h. Following TNFtz 
treatment both cytosolic and particulate PKC activities 
dropped to about half of control evels within 2 h, but 
were not restored afterwards. Thus there seems to be no 
linear correlation between TNFg-induccd alteration of  
fibroblast growth rate and PKC activity. However, one 
cannot rule out that PKC may be involved in this proc- 
ess in a more complex manner. We also observed that 
TPA-induced cell growth inhibition was partially re- 
versed by TNF~z. This effect was obsereed not only at 
24 h, when TNFg acted as a mitogen, but also at 2 h, 
when it acted as growth inhibitor. We therefore suppose 
155 
Volume 304, number 2,3 FEBS LETTERS June 1992 
that this effect may be a result of TNF0:-induced reduc- 
tion of total PKC available for activation by TPA. This 
is consistent with the notion that PKC activation may 
be responsible for the fibroblast growth inhibition 
caused by TPA. 
The complexity and incomplete understanding of the 
PKC signal transduction system allow us only to specu- 
late about the PKC-dependent mechanisms of negative 
regulation. However, several working hypotheses may 
provide a basis for further experiments. So far at least 
seven isoforms of PKC have been identified [3]. Activa- 
tion of one or more PKC isoforms may result in cell 
growth inhibition. PKC~t has been reported to phos- 
phorylate EGF receptor thereby making it insensitive to 
EGF [16]. Hence it is possible that excessive phospho- 
rylation of growth factor receptors by overactive PKC 
may lead to the desensitization of cells to extraeellular 
mitogens and consequently to growth inhibition. 
One can speculate that PKC overstimulation may 
alter oncogene xpression or the activity of  oncogene 
products thereby inhibiting cell proliferation. It was 
shown that TPA strongly inhibited c-H-ras oncogene- 
induced transformation of PKC-overproducing murine 
fibroblasts, but stimulated c-H.ras-induced transforma- 
tion of control cells with normal levels of PKC [2,17]. 
Other protooncogens (c-myc, c-fos) were also reported 
to be involved in PKC-mediated responses [18-20]. 
The system used in this work may serve as a conven- 
ient model to study the possible link between cell growth 
inhibition and PKC activation. Pure NCPI will be valu- 
able for future research. The purification process is now 
in progress in our laboratory. 
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